Article
Medicine, General & Internal
Zelong Yang, Yang Han, Guo Ting, Yifei Wang, He Kun, Haoran Hu, Chen Yong
Summary: High CCNF expression serves as an independent risk factor for poor survival in HCC and may be a potential target for the diagnosis and treatment of liver cancer.
Article
Cell Biology
Hao Wu, Jinrui Zhang, Yi Bai, Sai Zhang, Zhixin Zhang, Wen Tong, Pinsheng Han, Bing Fu, Yamin Zhang, Zhongyang Shen
Summary: Long non-coding RNAs (lncRNAs) and enhancer RNAs (eRNAs) have been shown to play important roles in tumor development, with DCP1A being identified as a potential novel biomarker for hepatocellular carcinoma (HCC) patients. High expression of DCP1A is associated with poor overall survival and advanced tumor characteristics in HCC patients, indicating its potential as a therapeutic target. Further functional analysis revealed the involvement of DCP1A in multiple tumor-related signaling pathways, suggesting its potential as a therapeutic target for HCC patients.
Article
Gastroenterology & Hepatology
Xiaopeng Cai, Jingwen Deng, Jiaming Zhou, Huiqiang Cai, Zhi Chen
Summary: CDK19 is significantly upregulated in hepatocellular cancer tissues and has high diagnostic value. CDK19 overexpression is associated with sex, tumor stage, and TP53 mutation status. Upregulation of CDK19 has significant prognostic value for overall survival in patients with stage 2-3, stage 3-4, and grade 2 disease.
BMC GASTROENTEROLOGY
(2021)
Article
Oncology
Matthis Desoteux, Corentin Louis, Kevin Bevant, Denise Glaise, Cedric Coulouarn
Summary: This study identified genes associated with hepatocyte differentiation in human HCC and developed a gene expression signature to predict poor prognosis. A minimal subset of seven differentiation-related genes was found to be clinically relevant for predicting the prognosis of HCC patients.
Article
Immunology
Qianqian Cheng, Wei Wang, Jing Liu, Zhenyu Lv, Wenbin Ji, Jinhui Yu, Wenting Zhang, Yan Yang
Summary: This study found that the elevated expression of MPP6 is associated with poor prognosis, angiogenesis, and immune evasion in hepatocellular carcinoma (HCC). Furthermore, MPP6 has the potential to assess tumor mutation burden (TMB) and treatment response. Therefore, MPP6 may serve as a novel prognostic biomarker and therapeutic target for HCC.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Dan-dan Xiong, Jian-di Li, Rong-quan He, Ming-xuan Li, Yan-qing Pan, Xiao-lian He, Yi-wu Dang, Gang Chen
Summary: This study found that CHST11 expression is upregulated in HCC and is associated with tumor progression and prognosis. It affects immune function in HCC by modulating pathways related to tumor growth, metastasis, and immune regulation, promoting Tregs infiltration and increasing PD-L1/PD-1 expression, resulting in immunosuppression. Targeting CHST11 may enhance the antineoplastic effect of immune checkpoint inhibitors.
Article
Oncology
Xin Liu, Yize Zhang, Zenghan Wang, Liwen Liu, Guizhen Zhang, Jianhao Li, Zhigang Ren, Zihui Dong, Zujiang Yu
Summary: The study reveals that PRRC2A is upregulated in HCC and associated with poor prognosis, acting as an independent risk factor. The activation of PRRC2A is significantly correlated with various oncogenic pathways. In vitro experiments confirm that silencing PRRC2A can inhibit the proliferation and metastasis capacities of HCC cells.
JOURNAL OF HEPATOCELLULAR CARCINOMA
(2021)
Article
Oncology
Qi Zhang, Yuxuan Wei, Yihu Li, Xingyuan Jiao
Summary: The study found that the macrophage receptor with collagenous structure (MARCO) is downregulated in hepatocellular carcinoma (HCC) and is associated with poor prognosis in patients. Low MARCO expression is correlated with high alpha-fetoprotein levels, high incidence of microvascular invasion, and a higher number of patients exceeding Milan criteria. MARCO could potentially serve as a prognostic marker and therapeutic target in post-liver transplantation HCC.
CANCER MANAGEMENT AND RESEARCH
(2022)
Article
Gastroenterology & Hepatology
Ah-Jung Jeon, Chukwuemeka George Anene-Nzelu, Yue-Yang Teo, Shay Lee Chong, Karthik Sekar, Lingyan Wu, Sin-Chi Chew, Jianbin Chen, Raden Indah Kendarsari, Hannah Lai, Wen Huan Ling, Neslihan Arife Kaya, Jia Qi Lim, Alexander Yaw Fui Chung, Peng-Chung Cheow, Juinn Huar Kam, Krishnakumar Madhavan, Alfred Kow, Iyer Shridhar Ganpathi, Tony Kiat Hon Lim, Wei-Qiang Leow, Shihleone Loong, Tracy Jiezhen Loh, Wei Keat Wan, Gwyneth Shook Ting Soon, Yin Huei Pang, Boon Koon Yoong, Diana Bee-Lan Ong, Jasmine Lim, Vanessa H. de Villa, Rouchelle D. dela Cruz, Rawisak Chanwat, Jidapa Thammasiri, Glenn K. Bonney, Brian K. P. Goh, Roger Sik Yin Foo, Pierce Kah-Hoe Chow
Summary: Through analyzing the tumors and normal tissues of 30 patients with early-stage hepatocellular carcinoma, we identified aberrant epigenetic events and genes associated with disease prognosis. We found genes that are associated with enhancers and their upregulation is associated with worse prognosis.
Article
Biochemistry & Molecular Biology
Haiyuan Li, Lei Gao, Xiaojuan Kang, Xueyan Wang, Yang Yu, Yaqing Zhang, Hao Chen
Summary: This study explored the expression and function of 40S ribosomal protein S24 (RPS24) in hepatocellular carcinoma (HCC). Results showed that RPS24 was elevated in HCC samples and related to poor prognosis. Furthermore, RPS24 overexpression or promoter methylation correlated with unfavorable prognosis in HCC patients. High expression of RPS24 was associated with DNA replication, cell cycle, immune infiltration, and immunotherapy response. Experimental validation demonstrated that silencing of RPS24 suppressed HCC cell growth and tumor proliferation. Therefore, RPS24 may serve as a potential adverse biomarker for HCC prognosis, acting through cell proliferation facilitation and the formation of an immunosuppressive microenvironment, and targeting RPS24 could be a promising therapeutic option for HCC management.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Yicong Yao, Yi Wang, Denglong Wu, Baoying Hu
Summary: The increased expression of CDC6 is potentially a poor prognostic factor in ccRCC patients. High CDC6 expression is correlated with malignant characteristics of tumors and multiple signaling pathways, as well as with immune-related factors, tumor microenvironment, and immune cell infiltration. The results from the TCGA database also show a significant relationship between CDC6 and immune checkpoint molecules and immune cells.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Ting Liu, Zhi-zhao Li, Lei Sun, Kun Yang, Jia-min Chen, Xiao-yi Han, Li-ming Qi, Xin-gang Zhou, Peng Wang
Summary: CANT1 is highly expressed in hepatocellular carcinoma (HCC) and is associated with clinical features and poor prognosis. It is involved in regulating biological processes such as cell cycle and DNA replication and is independently associated with immune cell infiltration and prognosis in HCC.
Article
Genetics & Heredity
Yingyun Guo, Binglu Huang, Ruixue Li, Jiao Li, Shan Tian, Cheng Peng, Weiguo Dong
Summary: In patients with hepatocellular carcinoma (HCC), APOA-1 mRNA expression is negatively regulated by DNA methylation. Low APOA-1 expression may serve as a potential risk biomarker for predicting survival in HCC patients. Additionally, high APOA-1 transcription correlates with better overall survival, and APOA-1 hypermethylation is associated with progress-free survival in HCC sufferers.
FRONTIERS IN GENETICS
(2021)
Article
Medicine, General & Internal
Yu Qian, He Wang, Ying Zhang, Jing-Wen Wang, Yu-Chen Fan, Shuai Gao, Kai Wang
Summary: This study found that high methylation of CCND2 is associated with poor prognosis and early tumor recurrence in patients with HBV-associated hepatocellular carcinoma. CCND2 methylation levels are correlated with the pathological characteristics of hepatocellular carcinoma and patient survival.
TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE
(2021)
Article
Biotechnology & Applied Microbiology
Guifu Wang, Xuesong Bai, Guoqing Jiang, Shengjie Jin, Qian Wang, Aoqing Wang, Rui Peng, Aiwu Ke, Dousheng Bai
Summary: GIT1 expression is elevated in HCC tissues, promoting invasion, migration, and proliferation of HCC cells, as well as inducing epithelial-mesenchymal transition (EMT) by activating the ERK1/2 pathway. It is associated with malignant features of HCC and poorer prognosis in patients.
